Written and reviewed by Akbar Zaib, PhD in Neurosciences
Tavapadon for Parkinson’s disease is a new treatment option approved by the U.S. FDA in September 2026. Sold under the brand name Juvmo, the once-daily medicine acts on dopamine receptors in a different way from many existing treatments. Here’s what patients and caregivers should know about how it works, the TEMPO studies and what the approval means.
What is tavapadon?
Tavapadon is a non-ergot dopamine agonist. The FDA approved it to treat Parkinson’s disease in adults in the United States. Its brand name is Juvmo. It is taken once daily, with or without food.
Dopamine agonists act on receptors normally activated by dopamine, a chemical messenger involved in movement. Tavapadon acts selectively on the D1 and D5 dopamine receptors. Many established dopamine agonists mainly act on D2 and D3 receptors. This difference is one reason researchers studied tavapadon, but it does not by itself prove the medicine is more effective or has fewer side effects.
How does tavapadon work in the brain?
In Parkinson’s disease, dopamine-producing nerve cells are gradually lost, especially in an area called the substantia nigra. This reduces dopamine signalling to movement circuits in another area of the brain, the striatum. Changes in these circuits can make it harder to start and control movement, contributing to symptoms such as slowness, stiffness and tremor.
Dopamine can bind to several receptor types. D1 and D5 are different subtypes from D2 and D3, and each can trigger different responses inside cells. The mechanism of tavapadon for Parkinson’s disease centres on its action at D1 and D5 receptors.
This differs from levodopa, which the brain converts into dopamine. Tavapadon binds directly to D1 and D5 receptors. It is a partial agonist, meaning it binds to and activates these receptors but produces a more limited response than a full agonist can. That pharmacology does not tell us how much benefit or how many side effects a particular person will experience.
Tavapadon acts on receptors; it does not restore lost nerve cells. It has not been shown to cure Parkinson’s disease or slow its progression.
Why was tavapadon studied, and what is TEMPO?
Researchers studied tavapadon to see whether stimulating dopamine receptors called D1 and D5 could help movement and everyday activities. They tested it on its own in people with early Parkinson’s disease and as an add-on to levodopa for people experiencing motor fluctuations.
TEMPO is the name of the clinical trial program. Its three main placebo-controlled Phase 3 trials studied tavapadon in different situations: TEMPO-1 and TEMPO-2 tested it on its own in people with early Parkinson’s disease, while TEMPO-3 tested it alongside levodopa in people with motor fluctuations. A Phase 3 trial is a later-stage study that assesses a medicine’s benefits and safety in a larger group of people.
TEMPO-4 was a 58-week open-label extension that looked at longer-term tavapadon use. “Open-label” means participants and researchers knew the participants were receiving tavapadon.
Results from TEMPO-3 were published in JAMA Neurology in 2026. Read the TEMPO-3 study.
What did the TEMPO trials find?
In TEMPO-1 and TEMPO-2, participants taking tavapadon had greater improvements in movement and activities of daily living at 26 weeks than participants receiving placebo. Researchers used a standard Parkinson’s disease rating scale that measures both motor symptoms and daily activities.
In TEMPO-3, participants taking tavapadon with levodopa gained an average of 1.7 hours per day of “on” time without troublesome dyskinesia, compared with 0.6 hours for those taking placebo with levodopa. Daily “off” time decreased by about 1.9 hours with tavapadon and 0.9 hours with placebo.
These are average results from trials. They cannot predict how much benefit one person may experience.
How does tavapadon compare with other dopamine agonists?
This table compares general features of tavapadon and selected D2/D3-targeting dopamine agonists, such as pramipexole and ropinirole. It is not a head-to-head comparison of effectiveness or safety.
| Feature | Tavapadon (Juvmo) | Selected D2/D3-targeting dopamine agonists |
|---|---|---|
| Receptor target | Selective partial agonist at D1 and D5 dopamine receptors | Mainly act on D2-like receptors; exact pharmacology varies by medicine |
| Dosing schedule | Oral tablet, once daily; dose is increased gradually | Depends on the medicine and formulation. Some immediate-release tablets are taken several times daily; extended-release versions may be once daily |
| Study settings | Studied without levodopa in early Parkinson’s and as an add-on to levodopa for motor fluctuations | Can be used alone or with levodopa, depending on the medicine and the person’s treatment plan |
| Safety points | Common effects include nausea, headache and dizziness. FDA warnings include low blood pressure, compulsive behaviours, hallucinations and dyskinesia | Side effects and warnings vary by product; may include nausea, dizziness, sleepiness, low blood pressure, hallucinations and compulsive behaviours |
This table compares general features. It is not a head-to-head comparison of effectiveness or safety.
What do the results tell us — and what remains unclear?
In TEMPO-1 and TEMPO-2, people with early Parkinson’s disease who took tavapadon had greater improvements in movement and activities of daily living at 26 weeks than people who received placebo. Researchers measured these outcomes using a standard Parkinson’s disease rating scale that includes motor symptoms and daily activities. A lower score on this scale means less impairment.
In TEMPO-3, people taking tavapadon with levodopa gained an average of 1.7 hours per day of “on” time without troublesome dyskinesia, compared with 0.6 hours for those taking placebo with levodopa. Daily “off” time decreased by about 1.9 hours with tavapadon and 0.9 hours with placebo.
In the open-label TEMPO-4 extension, AbbVie reported that at 85 weeks, 94% of participants with early Parkinson’s disease who were taking tavapadon without levodopa had not started levodopa (257 of 273). Among participants taking tavapadon with levodopa, 93% had not increased their levodopa dose (96 of 103). These results describe participants included in the extension analysis. Because the extension was open-label and had no placebo comparison, they do not prove tavapadon delayed the need for levodopa or prevented dose increases.
What does FDA approval mean for people with Parkinson’s?
FDA approval makes Juvmo a new prescription option for adults with Parkinson’s disease in the United States. The studies tested it without levodopa in people with early Parkinson’s disease and as an add-on to levodopa for people with motor fluctuations. That gives clinicians evidence about those situations, but it does not mean Juvmo is suitable for everyone or addresses every Parkinson’s symptom.
1. Don’t change current medication on your own.
An approval announcement is not a reason to stop levodopa, change a dose or adjust medication timing. A neurologist can advise whether tavapadon is relevant to an individual treatment plan.
2. Once daily may simplify one part of the routine.
Juvmo is taken once daily, with or without food. That may mean one scheduled dose of tavapadon, but it does not necessarily replace other Parkinson’s medicines or their doses.
3. The dose is increased gradually.
The FDA label includes a titration schedule. If prescribed, follow the clinician’s instructions and ask what to do if a dose is missed. Do not increase the dose faster than directed.
4. Keep track of changes after starting.
It may help to record changes in “on” and “off” time, movement and daily activities, dizziness when standing, nausea, hallucinations or unusual urges, and new or worsening involuntary movements. The FDA label warns about low blood pressure, compulsive behaviours, hallucinations and dyskinesia.
5. Ask whether it fits your situation and where you live.
The FDA approval applies to the United States; it does not establish approval or availability in Estonia or other countries. At an appointment, a patient or caregiver could ask: “Could tavapadon be relevant to my current symptoms and medication routine, and is it authorised where I live?”
For official information about Juvmo’s approved use, dosing, and warnings, see the FDA prescribing information for Juvmo (tavapadon).
Frequently Asked Questions About Tavapadon (Juvmo)
Clear answers to common questions about tavapadon for Parkinson’s disease.
Is tavapadon a cure for Parkinson’s disease?
No. Tavapadon is a prescription treatment intended to help manage Parkinson’s symptoms. It has not been shown to cure the disease or slow its progression.
How is tavapadon different from levodopa?
The brain converts levodopa into dopamine. Tavapadon works directly on D1 and D5 dopamine receptors as a partial agonist. They work in different ways, and tavapadon has not been shown to be better than levodopa in a head-to-head trial.
Can Juvmo be taken with levodopa?
Tavapadon was studied both without levodopa and as an add-on to levodopa. Whether to use it alone or with other Parkinson’s medicines is a decision for the prescribing clinician.
What did the TEMPO-3 study find?
At 26 weeks, participants taking tavapadon with levodopa gained an average of 1.7 hours of daily “on” time without troublesome dyskinesia, compared with 0.6 hours for those taking placebo with levodopa. “Off” time fell by about 1.9 hours and 0.9 hours, respectively.
What are common side effects of tavapadon?
Common side effects include nausea, headache and dizziness. The FDA label also warns about low blood pressure, compulsive behaviours, hallucinations and new or worsening dyskinesia. Side effects can differ when Juvmo is taken with levodopa.
Is Juvmo approved in Europe?
FDA approval applies to the United States and does not confirm approval or availability in other countries. Check with a neurologist or the local medicines authority for current status where you live.
Study source: Fernandez HH, et al. “Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.” JAMA Neurology. 2026;83(5):442–451. https://doi.org/10.1001/jamaneurol.2026.0577
Medical disclaimer: This article is for general educational purposes and is not a substitute for personal medical advice. FDA approval and availability of tavapadon (Juvmo) may vary by country. Do not start, stop, or change Parkinson’s medication without speaking with your neurologist or pharmacist.
Get Your Free Parkinson’s Medication Management Diary
Download your free printable diary to easily track your medications, symptoms, and doses.
